Alluvi, previously BI 4744, offers a significant advance in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive effectiveness in https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/